Values First Advisors Inc. Reduces Position in Exact Sciences Co. (NASDAQ:EXAS)

Values First Advisors Inc. lowered its holdings in Exact Sciences Co. (NASDAQ:EXAS) by 16.8% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 7,951 shares of the medical research company’s stock after selling 1,607 shares during the period. Values First Advisors Inc.’s holdings in Exact Sciences were worth $447,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Chicago Partners Investment Group LLC grew its position in shares of Exact Sciences by 1.7% during the third quarter. Chicago Partners Investment Group LLC now owns 9,261 shares of the medical research company’s stock worth $651,000 after buying an additional 158 shares in the last quarter. Perigon Wealth Management LLC boosted its stake in Exact Sciences by 3.2% during the 4th quarter. Perigon Wealth Management LLC now owns 8,436 shares of the medical research company’s stock valued at $474,000 after acquiring an additional 264 shares during the last quarter. Huntington National Bank grew its holdings in Exact Sciences by 838.1% during the 3rd quarter. Huntington National Bank now owns 394 shares of the medical research company’s stock worth $27,000 after acquiring an additional 352 shares in the last quarter. CIBC Asset Management Inc increased its position in shares of Exact Sciences by 6.1% in the 3rd quarter. CIBC Asset Management Inc now owns 6,489 shares of the medical research company’s stock worth $442,000 after purchasing an additional 371 shares during the last quarter. Finally, Advisors Asset Management Inc. raised its stake in shares of Exact Sciences by 1.4% in the 3rd quarter. Advisors Asset Management Inc. now owns 28,650 shares of the medical research company’s stock valued at $1,952,000 after purchasing an additional 402 shares in the last quarter. Institutional investors and hedge funds own 88.82% of the company’s stock.

Exact Sciences Stock Down 1.4 %

Shares of Exact Sciences stock opened at $50.34 on Thursday. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.12 and a quick ratio of 1.93. Exact Sciences Co. has a 1-year low of $40.62 and a 1-year high of $79.62. The business’s fifty day moving average price is $56.66 and its two-hundred day moving average price is $60.13. The company has a market capitalization of $9.32 billion, a P/E ratio of -43.03 and a beta of 1.24.

Wall Street Analyst Weigh In

A number of research firms recently commented on EXAS. William Blair reiterated an “outperform” rating on shares of Exact Sciences in a research note on Monday, January 13th. Benchmark reiterated a “buy” rating and issued a $65.00 target price on shares of Exact Sciences in a research report on Monday, January 13th. Sanford C. Bernstein upped their price target on Exact Sciences from $75.00 to $90.00 and gave the company an “outperform” rating in a research report on Wednesday, October 30th. Stifel Nicolaus decreased their price objective on shares of Exact Sciences from $82.00 to $67.00 and set a “buy” rating for the company in a report on Wednesday, November 6th. Finally, Barclays initiated coverage on shares of Exact Sciences in a report on Thursday, January 23rd. They set an “overweight” rating and a $70.00 target price on the stock. One research analyst has rated the stock with a hold rating and eighteen have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $72.76.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.